摘要
目的探讨胸腺五肽联合美托洛尔治疗高血压性心脏病的临床疗效。方法将94例高血压性心脏病患者按随机数字表法分为对照组和观察组,每组47例。对照组给予常规治疗,同时采用酒石酸美托洛尔片治疗。观察组在对照组治疗的基础上采用注射用胸腺五肽治疗。观察2组治疗前、治疗3个月后收缩压、舒张压和血浆氨基末端B型脑钠肽前体(NT-proBNP)、心肌肌钙蛋白Ⅰ(cTnⅠ)及左心室质量指数(LVMI)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)的水平。结果2组治疗前和治疗3个月后收缩压、舒张压水平比较差异无统计学意义(P>0.05)。2组治疗3个月后收缩压、舒张压水平均明显低于治疗前(均P<0.05)。观察组治疗3个月后LVMI、LVEDD水平和血浆NT-proBNP、cTnI水平均明显低于对照组,LVEF水平明显高于对照组,差异有统计学意义(P<0.05)。结论胸腺五肽联合美托洛尔治疗高血压性心脏病可有效地降低患者的血压,改善患者的心功能。
Objective To explore the clinical effect of thymopentin combined with metoprolol on hypertensive heart disease.Methods A total of 94 patients with hypertensive heart disease were randomly divided into control group and observation group,with 47 patients in each group.Both groups received routine treatment and metoprolol tartrate tablets.Additionally,the observation group was given thymopentin injection.Systolic blood pressure(SBP),diastolic blood pressure(DBP),plasma Amino-terminal pro-B-type natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI),left ventricular mass index(LVMI),left ventricular end-diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)were observed before and after treatment for 3 months.Results There were no significant differences in SBP and DBP between the two groups before and after treatment for 3 months(P>0.05).However,SBP and DBP after 3 months of treatment were lower than those before treatment in both groups(P<0.05).Compared with control group,the LVMI,LVEDD and plasma NT-proBNP and cTnI levels decreased but the LVEF increased in observation group after treatment for 3 months(P<0.05).Conclusion Thymopentin combined with metoprolol can effectively reduce blood pressure and improve heart function in patients with hypertensive heart disease.
作者
林桐梅
高苗
LIN Tong-mei;GAO Miao(Department of Hypertensive Cardiology,Anyang Sixth People’s Hospital,Anyang 455000,China;Department of Orthopedics,Anyang Sixth People’s Hospital,Anyang 455000,China)
出处
《实用临床医学（江西）》
CAS
2019年第8期14-16,19,共4页
Practical Clinical Medicine
